Dyslipidemia Management in Adults With Diabetes

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Elevated low-density lipoprotein (LDL) cholesterol and other lipid abnormalities are significant risk factors for atherosclerotic cardiovascular disease (ASCVD) in patients with type 2 diabetes.
• While diet and lifestyle modifications are foundational, pharmacological interventions are crucial for managing dyslipidemia and preventing ASCVD in this population.

Purpose of the Study:

• To review current and emerging lipid-lowering therapies for ASCVD prevention in patients with type 2 diabetes.
• To evaluate the efficacy of various drug classes, including statins, ezetimibe, PCSK9 inhibitors, and others, in managing diabetic dyslipidemia and reducing cardiovascular risk.

Main Methods:

• Systematic search of English language randomized controlled trials (RCTs) of lipid-lowering therapies in patients with diabetes, focusing on studies published since 2012.
• Analysis of treatment outcomes related to LDL cholesterol reduction, triglyceride levels, and ASCVD risk reduction.

Main Results:

• Statins remain the cornerstone therapy for reducing LDL cholesterol and ASCVD risk in diabetic patients.
• Ezetimibe, proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors (alirocumab, evolocumab), and high-dose icosapent ethyl demonstrate significant benefits, particularly in high-risk or statin-treated patients with elevated triglycerides.
• Fibrates may offer benefits for ASCVD risk in specific lipid profiles and are recommended for pancreatitis prophylaxis and potentially slowing diabetic retinopathy progression.

Conclusions:

• A range of pharmacotherapies effectively reduce ASCVD risk in type 2 diabetes by targeting LDL cholesterol and triglycerides.
• Novel therapies, including antisense oligonucleotides and monoclonal antibodies, show promise for future management of diabetic dyslipidemia.